Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis
Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 3932-3938
DOI: 10.1016/j.jtha.2026.08.009 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Milan Vujčić und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology, University Hospital of Split, Croatia. Electronic address: milan.vujcic@kbsplit.hr. Hauptthemen laut MEDLINE: von Willebrand Diseases, Antibodies, Monoclonal, Humanized, Gastrointestinal Hemorrhage, Multiple Myeloma. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We report the first case of emicizumab prophylaxis in refractory acquired von Willebrand syndrome secondary to multiple myeloma. A 72-year-old woman with IgG κ multiple myeloma and gastrointestinal angiodysplasia suffered recurrent life-threatening hemorrhage unresponsive to multimodal therapies, including factor concentrates, intravenous immunoglobulin, plasmapheresis, and endoscopic interventions. Subcutaneous emicizumab combined with octreotide, ongoing anti-myeloma therapy, and previous endoscopic control achieved complete cessation of bleeding despite persistently undetectable von Willebrand factor activity. Over 12 months of follow-up, the patient maintained a very good partial response and remained transfusion-free with an Eastern Cooperative Oncology Group performance status of 0. This case suggests that emicizumab-mediated restoration of secondary hemostasis can provide sustained bleeding control in refractory acquired von Willebrand syndrome when combined with a multidisciplinary approach, offering a valuable therapeutic option when conventional hemostatic measures fail.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hematology, University Hospital of Split, Croatia. Electronic address: milan.vujcic@kbsplit.hr.
- Department of Internal Medicine, Division of Hematology, University Hospital of Split, Croatia.
- Department of Internal Medicine, Division of Hematology, University Hospital of Split, Croatia; Department of Internal Medicine, University of Split, School of Medicine, Croatia.
- Department of Internal Medicine, Division of Hematology, University Hospital of Zagreb, Croatia.
- Department of Internal Medicine, Division of Hematology, University Hospital of Zagreb, Croatia; Department of Internal Medicine, University of Zagreb, School of Medicine, Croatia.
Zitieren
APA
Vujčić, M., Madunić, S., Jakelić Piteša, J., Petrić, M., Galušić, D., Ranković, E., & Boban, A. (2026). Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis. Journal of Thrombosis and Haemostasis, 24(11), 3932-3938. https://doi.org/10.1016/j.jtha.2026.08.009
Vancouver
Vujčić M, Madunić S, Jakelić Piteša J, Petrić M, Galušić D, Ranković E, et al. Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis. Journal of Thrombosis and Haemostasis. 2026;24(11):3932-3938. doi:10.1016/j.jtha.2026.08.009
BibTeX
@article{Vuji2026,
author = {Vujčić, Milan and Madunić, Sanja and Jakelić Piteša, Jasminka and Petrić, Marija and Galušić, Davor and Ranković, Ena and Boban, Ana},
title = {Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {11},
pages = {3932--3938},
doi = {10.1016/j.jtha.2026.08.009}
}
EUVIMED